Doug Ingram

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared by more than 10 percent Wednesday after the company reported encouraging results from a clinical trial of a therapy intended to treat Duchenne muscular dystrophy (DMD). Sarepta's drug called golodirsen showed that patients who suffer from...

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares jumped up over 17 percent during Wednesday’s after-hours trading sessions, after the medical research and drug development company crushed earnings estimates. A Closer Look At Q2 Earnings Revenue: $35 million (consensus estimate was $22.3...

Credit Suisse analyst Alethia Young reiterated an Outperform rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) with a $64 price target, following the announcement of a new CEO and ahead of several other catalysts. Sarepta announced Wednesday that Doug Ingram has been appointed CEO. He will...

Allergan, Inc. (NYSE: AGN) has been on a roll in the past year. Not only did the company crushed Bill Ackman’s attempt of taking it over, it also posted record numbers for the fiscal year and the shares are up over 80 percent year over year. David Pyott, Allergan chairman and CEO, was on...